western-blotting and labelling with TauN and PS396 antibodies, respectively. . Cognitive deficit in aged double-transgenic APP(SW)/Tau(VLW) mice as.
43.10/I11
GLYCOGEN SYNTHASE KINASE-3β (GSK-3β) INHIBITION AS A PROMISING DRUG TARGET FOR THE TREATMENT OF COMORBID ALZHEIMER’S DISEASE OR SCHIZOPHRENIA, AND DEPRESSION G. Griebel1, P. Pichat1, S. Beeské1, D. Boulay1, M. Lopez-Grancha2, J. Stemmelin2, C. Cohen2, G. Boquet3, P. Avenet1, O. Curet1 1
Sanofi, Exploratory Unit, Chilly-Mazarin, France • 2 Sanofi, Therapeutic Strategic Unit Aging, Chilly-Mazarin, France • 3 Sanofi, Global Biotherapeutics, Vitry, France
Results TESTS RELATED TO POTENTIAL EFFICACY AGAINST AD
PCP challenge 1.5 mg/kg i.p.
SAR502250 (3-10-30 mg/kg p.o.)
Figure 2
Experimental design
■ Conditioned active avoidance (CAR) in mice CAR behavior was assessed using automated two-way shuttle boxes. C57BL/6J mice were trained for 3 days-a-week to move into the adjacent compartment (avoidance) within 15 s upon presentation of the conditioned stimulus (light) in order to avoid the appearance of the unconditioned stimulus, a 0.4 mA scrambled electric foot shock of 20 s in maximal duration. Shuttle responses performed during the 15-second avoidance period were recorded as avoidance responses and no shock was received. Each daily test session consisted of 40 trials. SAR502250 was administered orally 60 minutes prior to testing. Note: No potential conflict of interest
